Abstract An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19. An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for > 120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19.
All Keywords
【저자키워드】 COVID‐19, interferon, ruxolitinib, 【초록키워드】 combination therapy, COVID‐19, Asymptomatic, female, Viral RNA, Support, observation, SARS‐CoV‐2 infection, positive, RT‐PCR, viral RNA clearance, remained, 【제목키워드】 response, myelofibrosis, treated,
【저자키워드】 COVID‐19, interferon, ruxolitinib, 【초록키워드】 combination therapy, COVID‐19, Asymptomatic, female, Viral RNA, Support, observation, SARS‐CoV‐2 infection, positive, RT‐PCR, viral RNA clearance, remained, 【제목키워드】 response, myelofibrosis, treated,